IMPACT OF TUMOUR INFILTRATING LYMPHOCYTES (TILS) & TUMOUR REGRESSION IN PRIMARY CUTANEOUS MELANOMA ON RESPONSE TO IMMUNE CHECKPOINT INHIBITOR (ICI) THERAPY

被引：0
|
作者：
Mcmullen, Michelle [1 ]
Martin, Hilary [1 ,2 ]
Tan, Rebekah [2 ]
Leng, Weijie [2 ]
Ohara, Kanako [1 ]
Khattak, Muhammad [1 ,2 ,3 ]
机构：
[1] Fiona Stanley Hosp, Wembley, WA, Australia
[2] Univ Western Australia, Perth, WA, Australia
[3] Edith Cowan Univ, Perth, WA, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
203
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [21] Correlation between the density of tumour-infiltrating lymphocytes, immune cell subsets in tumour stroma and response to systemic therapy in breast cancer
    Kuhar, C. Grasic
    Gersak, K.
    Gazic, B.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen Melan-A/MART-1
    Saleh, FH
    Crotty, KA
    Hersey, P
    Menzies, SW
    INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (04) : 551 - 557
  • [23] Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma
    Vasaturo, Angela
    Di Blasio, Stefania
    Verweij, Dagmar
    Blokx, Willeke A. M.
    van Krieken, J. Han
    de Vries, I. Jolanda M.
    Figdor, Carl G.
    HISTOPATHOLOGY, 2017, 70 (04) : 643 - 649
  • [24] Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibitionerefractory advanced cutaneous melanoma
    Pillai, M.
    Hawkins, R. E.
    Jiang, Y.
    Lorigan, P. C.
    Thistlethwaite, F.
    Thomas, M.
    Kirillova, N.
    Bridgeman, J. S.
    Kueberuwa, G.
    Guest, R. D.
    Roberts, Z. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S882 - S882
  • [25] Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment
    Hakansson, A
    Gustafsson, B
    Krysander, L
    Hakansson, L
    BRITISH JOURNAL OF CANCER, 1996, 74 (05) : 670 - 676
  • [26] The value of tumour infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a study in a hospital complex
    Cordoba, A.
    Ruiz de Azua, Y.
    Arean, C.
    Aguiar, B.
    Nova, L.
    Labiano, T.
    Ulazia, A.
    Guerrero, D.
    VIRCHOWS ARCHIV, 2018, 473 : S56 - S56
  • [27] Outcome of metastatic melanoma following immune checkpoint inhibitor treatment by tumor infiltrating lymphocyte of primary cutaneous site.
    Hegde, Upendra P.
    Holmes, Aaron N.
    Stevenson, Christina Elizabeth
    Masternak, Sophie
    Bethany, Cucka
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy
    Jackson-Carroll, Natalie
    Johnson, Constance
    Tawbi, Hussein
    Wang, Xin Shelley
    Whisenant, Meagan
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [29] Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
    Schuiveling, M.
    van Duin, I.
    ter Maat, L. S.
    Van den Berkmortel, F. W. P. J.
    Boers-Sonderen, M. J.
    de Groot, J. W.
    Kapiteijn, E.
    Labots, M.
    Piersma, D.
    Schrader, A. M. R.
    Vreugdenhil, G.
    Westgeest, H. M.
    Pluim, J.
    Veta, M.
    Blokx, W. A.
    van Diest, P. J.
    Suijkerbuijk, K. P. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S675 - S675
  • [30] Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
    Warner, A. Betof
    Smithy, J. W.
    Los, C.
    Kalvin, H.
    Hasson, N.
    Amaria, R. N.
    Czapla, J. A. Andrade
    Schollenberger, M.
    Furness, A.
    Hassel, J. C.
    Wermke, M.
    Gallegos, J. A. Ocejo
    Lutzky, J.
    Lipson, E. J.
    Sullivan, R. J.
    Kluger, H.
    Panageas, K.
    Klobuch, S.
    Haanen, J. B. A. G.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2024, 35 : S730 - S731
12345